Innovative Biotechnologies Acquired by Privately Held Rheonix, Inc.

GRAND ISLAND, NY — December 31, 2008 — Richard A. Montagna, President of Innovative Biotechnologies International, Inc. ("IBI"), today announced the successful completion of an acquisition by privately-held, Ithaca, NY-based Rheonix, Inc. The ability to integrate the biosensor capabilities of IBI, developed in collaboration with scientists at Cornell University with Rheonix's novel CARD™ (Chemistry And Reagent Device) microfluidic technology, will provide a fully automated "point-of-care" (POC) or "point-of-use" (POU) diagnostic… Read More »

Rheonix, Next-Generation in vitro Diagnostic Systems Company, Receives New York State Innovation Award for Bio International 2008

ITHACA, N.Y. – March 25, 2008 – Rheonix Inc., an in vitro diagnostics systems company pioneering single chip, fully-integrated microfluidic systems for near-patient and point-of-care molecular identification of infectious disease and other applications, announced that it has been selected by the New York State Senate and NYSTAR to receive one of two Innovations Awards, which will support the Company’s participation in Bio International 2008. Founded in 2007, Rheonix’s technology is based… Read More »
Rheonix receives FDA Emergency Use Authorization for Automated COVID-19 Test.
Learn More